Australia Expands High-Dose Omega-3 Access for Heart Disease Patients

Omega-3 fatty acids remain one of the most widely used dietary supplements, known primarily for their heart health benefits. A 2023 study confirmed that higher doses of these fats lead to clearer improvements in key cardiovascular risk factors. Now, Australia's Pharmaceutical Benefits Scheme (PBS) has expanded access to a high-dose omega-3 treatment for patients at elevated risk of heart disease.

Omega-3s, found in fish oil, play a vital role in maintaining cell membrane function and fluidity. Their best-documented effect is lowering triglycerides, a type of fat linked to heart health. However, standard fish oil capsules typically provide only around 300 mg of combined EPA and DHA—the two most important omega-3s. Research shows that doses above 2 grams per day are needed to significantly cut triglyceride levels.

Beyond heart health, omega-3s—especially EPA—have been found to modestly ease symptoms of clinical depression when taken alongside antidepressants. They also offer mild anti-inflammatory benefits, reducing joint tenderness in conditions like inflammatory arthritis. Side effects from fish oil are usually mild, such as a fishy aftertaste, slight nausea, or diarrhoea.

In October 2024, Australia's PBS listed Vazkepa (icosapent ethyl), a high-dose EPA drug, for specific high-risk patients. Eligible adults include those aged 45 or older with atherosclerosis, or 50 and above with diabetes plus at least one extra risk factor. They must also have experienced a recent heart health event within the past year or have stable heart disease with raised triglycerides (4.0–<10.0 mmol/L), despite statin treatment. The decision follows evidence from the REDUCE-IT trial, which showed a 20% or greater reduction in major cardiovascular events with the drug.

The Heart Foundation advises Australians to eat two to three servings of oily fish weekly to meet omega-3 needs. For those requiring higher doses, prescription options like Vazkepa now provide a targeted approach.

The PBS listing of Vazkepa reflects growing recognition of omega-3s' role in managing heart health risk. Patients meeting strict medical criteria can now access the high-dose treatment at a subsidised cost. Meanwhile, dietary sources and standard supplements continue to offer broader but lower-level benefits for general health.